| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-11-2272 |
| P8608 | Fatcat ID | release_wd5nfilr75g7vbybu5sdmr2syu |
| P932 | PMC publication ID | 3261584 |
| P698 | PubMed publication ID | 22252257 |
| P2093 | author name string | Qian Shi | |
| Tsung-Teh Wu | |||
| Axel Grothey | |||
| William R Sukov | |||
| Harry H Yoon | |||
| Robert B Diasio | |||
| Robert B Jenkins | |||
| Frank A Sinicrope | |||
| Maliha Khan | |||
| Christopher A Sattler | |||
| Anne E Wiktor | |||
| P2860 | cites work | Adenocarcinomas of esophagus and cardia in comparison with gastric carcinoma | Q72680681 |
| Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group | Q77363051 | ||
| Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus | Q79401515 | ||
| HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial | Q79816337 | ||
| The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence | Q81290009 | ||
| HER-2/neu expression in locally advanced breast carcinomas: pre-and post-neoadjuvant chemotherapy | Q81478000 | ||
| Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma | Q81621756 | ||
| Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines | Q83722585 | ||
| Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis | Q24602426 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence | Q30837765 | ||
| Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals | Q33610263 | ||
| Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus | Q33611018 | ||
| The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection | Q34374254 | ||
| Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review | Q34605352 | ||
| Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review | Q34631121 | ||
| Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus | Q34761782 | ||
| HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. | Q35111575 | ||
| The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study | Q35163880 | ||
| Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. | Q35354276 | ||
| Chemoradiation in the management of esophageal cancer | Q36935105 | ||
| Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients | Q37135262 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry | Q37205563 | ||
| c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus | Q37256684 | ||
| Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer | Q37626334 | ||
| HER2 testing in gastric cancer | Q37822236 | ||
| Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. | Q38412375 | ||
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | Q39605778 | ||
| Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus | Q39977382 | ||
| Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. | Q40622495 | ||
| HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing | Q42431264 | ||
| High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates | Q42521534 | ||
| Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists | Q46378890 | ||
| Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. | Q51741363 | ||
| Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? | Q53410042 | ||
| Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. | Q54594739 | ||
| Expression of Her-2 in carcinomas of the esophagus. | Q54630658 | ||
| HER-2 amplification is highly homogenous in gastric cancer. | Q54709456 | ||
| Esophageal Cancer | Q56209683 | ||
| Barrett's oesophagus is characterized by a predominantly humoral inflammatory response | Q57939544 | ||
| Significance of HER2 Low-Level Copy Gain in Barrett's Cancer: Implications for Fluorescence In situ Hybridization Testing in Tissues | Q60056797 | ||
| Gains and Amplifications of c-myc, EGFR, and 20.q13 Loci in the No Dysplasia-Dysplasia-Adenocarcinoma Sequence of Barrett's Esophagus | Q61814005 | ||
| Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer | Q69926364 | ||
| Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas | Q70891361 | ||
| Comparative studies of cardia carcinoma and infracardial gastric carcinoma | Q72680677 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 546-554 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas | |
| P478 | volume | 18 |
| Q36097775 | A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy |
| Q47757344 | A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion |
| Q58763391 | A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas |
| Q38153443 | Advances in biomarkers for esophageal cancer |
| Q36910400 | Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma |
| Q33709855 | Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma |
| Q40619773 | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications |
| Q34852929 | Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas |
| Q39114318 | Bile acid at low pH reduces squamous differentiation and activates EGFR signaling in esophageal squamous cells in 3-D culture |
| Q39751816 | Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma |
| Q54501808 | Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. |
| Q36410392 | Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma. |
| Q35151182 | Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies. |
| Q40107322 | Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens |
| Q36666667 | Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. |
| Q49571137 | EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. |
| Q38392935 | EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer |
| Q43712233 | Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial |
| Q57072196 | Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer |
| Q38284597 | Emerging mAbs for the treatment of esophagogastric cancer |
| Q38110962 | Emerging tyrosine kinase inhibitors for esophageal cancer |
| Q38968846 | ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways |
| Q37328638 | Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer |
| Q89391950 | Gastric cancer |
| Q36020920 | HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. |
| Q37599574 | HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma |
| Q89879114 | HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q41839228 | HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma |
| Q26741253 | HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice |
| Q53657591 | HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. |
| Q30837184 | HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer |
| Q37522215 | HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis |
| Q90242172 | HER2-targeted therapies - a role beyond breast cancer |
| Q60915393 | HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma |
| Q42936269 | Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus |
| Q55014435 | Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma. |
| Q34223494 | Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications |
| Q51103473 | Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma. |
| Q39069439 | Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study |
| Q34559419 | Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force |
| Q35051918 | Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis |
| Q90271677 | Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma |
| Q38316610 | Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach |
| Q99565418 | Investigation of HER-2 Expression an Its Correlation with Clinicopathological Parameters and Overall Survival of Esophageal Squamous Cell Carcinoma Patients |
| Q40571939 | Lipase member H frequently overexpressed in human esophageal adenocarcinomas |
| Q34820809 | MALDI imaging on large-scale tissue microarrays identifies molecular features associated with tumour phenotype in oesophageal cancer. |
| Q47967299 | Met, IGF1R, and other new targets in upper GI malignancies |
| Q33750142 | Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade |
| Q58783978 | New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment |
| Q38653309 | Pertuzumab in gastrointestinal cancer |
| Q39115912 | STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas. |
| Q35619400 | STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells |
| Q34409666 | Strategies to improve outcomes in esophageal adenocarcinoma. |
| Q28085367 | Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma |
| Q35037270 | Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer |
| Q38254375 | The potential for targeting HER2 therapeutically in esophageal cancer - a grasp at straws? |
| Q28069924 | The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 |
| Q89700506 | Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer |
| Q55039208 | Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression. |
| Q87376791 | [Update on Barrett esophagus and Barrett carcinoma] |
Search more.